Default company panoramic image
151ddbbc 17b0 4de7 b9da 7397a8a850a7

Ischemix, Inc.

Clinical-stage pharmaceutical company with portfolio of therapeutics for prevention and treatment of serious cardiac and renal conditions.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Maynard, MA, USA
  • Currency USD
  • Founded June 1999
  • Employees 7
  • Website ischemix.com

Company Summary

Ischemix is a privately-held, clinical-phase pharmaceutical company developing a portfolio of therapeutic compounds for the prevention and treatment of serious cardio-renal conditions. There are no currently available therapies for the conditions the Company seeks to treat. Ischemix expects to initially market its lead compound to the critical care area of the hospital.

Team

  • Default avatar
    David DeWahl
    President and Chief Executive Officer

    Mr. DeWahl joined Ischemix in January 2013 as President and Chief Executive Officer. He was previously Vice President of Corporate Development for Helix Therapeutics, Inc. Mr. DeWahl is also a co-founder of Life Science Pharmaceuticals, Inc., which is developing novel therapeutics to treat cancer, diabetes and other serious illnesses. Mr. DeWahl was previously an investment banker focused on the health care and life sciences industry

Advisors

  • Default avatar
    Cooley LLP
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    Reinier Beeuwkes PhD
    Unconfirmed
    Default avatar
    Geoffrey Clark MD
    Unconfirmed